Condition (MeSH)
Goldenhar Syndrome
ClinicalTrials.gov lists 13 trials for Goldenhar Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Goldenhar Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Goldenhar Syndrome trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2015 | 3 |
| 2013 | 1 |
| 2012 | 1 |
| 2010 | 1 |
| 2005 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Goldenhar Syndrome trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Not applicable | 6 |
| Observational | 5 |
How many Goldenhar Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 9 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Goldenhar Syndrome trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Human Genome Research Institute (NHGRI) | 1 |
| Zimmer Biomet | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cultured ASCs enrichment fat grafting | 1 |
| Bone Marrow Aspirate Concentrate | 1 |
| type A botulinum toxin | 1 |
| Curcumin-preconditioned ASCs enrichment fat grafting | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Goldenhar Syndrome? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Difficult airway management using Pentax-AWS Airwayscope with pediatric Intlock and tracheal tube introducer in Goldenhar syndrome patient. | Journal of clinical anesthesia | 2016 | Yes |
| Precise positioning of an intraoral distractor using augmented reality in patients with hemifacial microsomia. | Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery | 2015 | Yes |
| Airway management using the pediatric GlideScope in a child with Goldenhar syndrome and atypical plasma cholinesterase. | Paediatric anaesthesia | 2007 | Yes |
| Mandibular distraction in neonates: indications, technique, results. | Italian journal of pediatrics | 2012 | No |
| Immediate mandibular distraction in mandibular hypoplasia and upper airway obstruction. | The Journal of craniofacial surgery | 2012 | No |
Prevalence (5)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Craniofacial microsomia | Prevalence at birth | 1-9 / 1 000 000 | France | Not stated | Unspecified |
| Craniofacial microsomia | Prevalence at birth | 1-5 / 10 000 | Australia | Not stated | Unspecified |
| Craniofacial microsomia | Prevalence at birth | 1-9 / 100 000 | Worldwide | Not stated | Unspecified |
| Craniofacial microsomia | Point prevalence | 1-9 / 100 000 | Worldwide | Not stated | Unspecified |
| Craniofacial microsomia | Point prevalence | 1-9 / 100 000 | Japan | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Goldenhar syndrome | 374 | Exact | Orphadata Science knowledge files, Product 1 |
| Goldenhar syndrome | 374 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.